FY2026 EPS Estimates for CervoMed Raised by HC Wainwright

CervoMed Inc. (NASDAQ:CRVO) – Investment analysts at HC Wainwright upped their FY2026 earnings per share estimates for shares of CervoMed in a research report issued on Thursday, July 9th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of ($2.70) for the year, up from their previous estimate of ($2.77). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for CervoMed’s Q4 2026 earnings at ($0.59) EPS, Q1 2027 earnings at ($0.51) EPS, Q2 2027 earnings at ($0.46) EPS, Q3 2027 earnings at ($0.50) EPS, Q4 2027 earnings at ($0.53) EPS and FY2027 earnings at ($1.99) EPS.

Several other equities analysts have also commented on CRVO. Roth Capital set a $9.00 price target on shares of CervoMed in a research report on Monday, May 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of CervoMed in a research note on Monday, April 20th. Chardan Capital upped their target price on shares of CervoMed from $15.00 to $21.00 and gave the stock a “buy” rating in a research report on Wednesday, March 18th. Finally, D. Boral Capital restated a “buy” rating and issued a $31.00 price target on shares of CervoMed in a research note on Wednesday, April 22nd. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, CervoMed currently has an average rating of “Moderate Buy” and an average target price of $22.60.

CervoMed Stock Performance

CRVO stock opened at $3.57 on Monday. CervoMed has a 1 year low of $2.13 and a 1 year high of $13.13. The stock has a market capitalization of $48.29 million, a price-to-earnings ratio of -1.09 and a beta of -0.68. The stock’s fifty day moving average is $3.36 and its two-hundred day moving average is $4.55.

CervoMed (NASDAQ:CRVO) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.86) EPS for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.04. CervoMed had a negative return on equity of 136.08% and a negative net margin of 672.80%.

Insider Transactions at CervoMed

In other CervoMed news, Director Joshua S. Boger purchased 955,414 shares of the firm’s stock in a transaction dated Thursday, June 11th. The stock was bought at an average price of $3.14 per share, with a total value of $2,999,999.96. Following the completion of the purchase, the director owned 1,795,865 shares in the company, valued at $5,639,016.10. This trade represents a 113.68% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 35.80% of the company’s stock.

Institutional Investors Weigh In On CervoMed

Hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in CervoMed by 1.0% in the third quarter. Vanguard Group Inc. now owns 343,463 shares of the company’s stock worth $2,779,000 after purchasing an additional 3,445 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in CervoMed by 8,425,900.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 84,260 shares of the company’s stock valued at $666,000 after buying an additional 84,259 shares during the period. Jane Street Group LLC acquired a new position in CervoMed during the 2nd quarter valued at about $414,000. Renaissance Technologies LLC bought a new stake in shares of CervoMed during the 1st quarter worth about $252,000. Finally, Byrne Asset Management LLC raised its position in shares of CervoMed by 248.6% during the 2nd quarter. Byrne Asset Management LLC now owns 51,250 shares of the company’s stock worth $159,000 after buying an additional 36,550 shares in the last quarter. 25.15% of the stock is currently owned by institutional investors.

About CervoMed

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc was founded in 2010 and is headquartered in Boston, Massachusetts.